Evidence map›Paper›PMID 39611611›Full record

Trial reportHuman vaccines & immunotherapeutics2024

Safety, tolerability, and efficacy of intranasally-administered detoxified LTh(αK) in mild-to-moderate COVID-19 patients: A randomized, double-blinded, placebo-controlled phase 2 study.

Chien-Yu Cheng, Ying-Shih Su, Chyi-Liang Chen, Mingi Chang, Shu-Wei Huang, Peng-Nien Huang, Shin-Ru Shih, Yu-Shen Hsu, Cheng-Hsun Chiu

Abstract readRandomized Controlled TrialClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chien-Yu ChengDepartment of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan.ORCID 0000-0002-1886-0370
Ying-Shih SuInternational Intercollegiate Ph.D. Program, National Tsing Hua University, Hsinchu, Taiwan.
Chyi-Liang ChenMolecular Infectious Disease Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.ORCID 0000-0003-4591-0924
Mingi ChangAdvagene Biopharma Co., Ltd., Taipei, Taiwan.ORCID 0000-0003-3142-4191
Shu-Wei HuangDepartment of Orthopedics, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.ORCID 0000-0003-3251-9918
Peng-Nien HuangResearch Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan, Taiwan.ORCID 0000-0002-7345-2361
Shin-Ru ShihResearch Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan, Taiwan.ORCID 0000-0003-4874-401X
Yu-Shen HsuAdvagene Biopharma Co., Ltd., Taipei, Taiwan.
Cheng-Hsun ChiuMolecular Infectious Disease Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.ORCID 0000-0003-4324-7743

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of the study was to assess the safety, tolerability, and potential efficacy of intranasally administered AD17002, a detoxified form of

Indexed as

Administration, IntranasalCOVID-19EnterotoxinsSARS-CoV-2AdultAgedBacterial ToxinsCOVID-19 Drug TreatmentDouble-Blind MethodEscherichia coli ProteinsFemaleHumansImmunologic FactorsMaleMiddle AgedTaiwanBacterial ToxinsEnterotoxinsEscherichia coli Proteinsheat-labile enterotoxin, E coliImmunologic FactorsCOVID-19immunomodulatorIntranasalsafetyviral load

Identifiers

PMID39611611
PMCPMC11610553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.